Pathology: es-BC - TNBC - NA - all population; mBC - TNBC - L1 - all population; mBC - TNBC - L1 - PDL1 positive; mBC - TNBC - L2 - all population; mBC - TNBC - L2 - PDL1 positive;
| es-BC - TNBC - NA - all population | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | ||||
| KEYNOTE-522, 2020 | KEYNOTE-355 (all population), 2020 | KEYNOTE-355 (CPS>1), 2020 | KEYNOTE-355 (CPS>10), 2020 | KEYNOTE-119 (all population), 2019 | KEYNOTE-119 (PDL1 CPS>1), 2019 | KEYNOTE-119 (PDL1 CPS>10), 2019 | ||
| pembrolizumab alone | 4 | T1 | T1 | T1 | T1 | |||
| pembrolizumab plus SoC | 3 | T1 | T1 | T1 | ||||
| placebo | 0 | T0 | ||||||
| placebo plus SoC | 0 | T0 | T0 | T0 | ||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | ||||